Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma.

Despite extensive genetic diversity of HIV-1 in chronic infection, a single or few maternal virus variants become the founders of an infant's infection. These transmitted/founder (T/F) variants are of particular interest, as a maternal or infant HIV vaccine should raise envelope (Env) specific...

Full description

Bibliographic Details
Main Authors:	Amit Kumar, Claire E P Smith, Elena E Giorgi, Joshua Eudailey, David R Martinez, Karina Yusim, Ayooluwa O Douglas, Lisa Stamper, Erin McGuire, Celia C LaBranche, David C Montefiori, Genevieve G Fouda, Feng Gao, Sallie R Permar
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-04-01
Series:	PLoS Pathogens
Online Access:	http://europepmc.org/articles/PMC5908066?pdf=render

Similar Items

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
by: David R. Martinez, et al.
Published: (2020-04-01)

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.
by: Nathanael P McCurley, et al.
Published: (2017-01-01)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
by: Fouda G, et al.
Published: (2012-09-01)

Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.
by: Amit Kumar, et al.
Published: (2021-04-01)

The Role of Maternal HIV Envelope-Specific Antibodies and Mother-to-Child Transmission Risk
by: Ayooluwa O. Douglas, et al.
Published: (2017-09-01)

Phenotypic properties of transmitted founder HIV-1.
by: Parrish, N, et al.
Published: (2013)

The Presence and Anti-HIV-1 Function of Tenascin C in Breast Milk and Genital Fluids.
by: Robin G Mansour, et al.
Published: (2016-01-01)

Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials
by: Eliza D. Hompe, et al.
Published: (2020-06-01)

Novel SHIVs encoding transmitted/founder Envs for latency and cure research
by: A. Bauer, et al.
Published: (2019-12-01)

Resistance of transmitted founder HIV-1 to IFITM-mediated restriction
by: Foster, T, et al.
Published: (2016)

Implications of viral transmitted/founder (T/F) dynamics on vaccine development
by: Alexander I. Mosa
Published: (2021-07-01)

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
by: Nicholas F Parrish, et al.
Published: (2012-01-01)

Phagocytic uptake of transmitted/founder virus-infected CD4+T cells enhances macrophage infection
by: Duncan, C, et al.
Published: (2012)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.
by: Goonetilleke, N, et al.
Published: (2009)

Josephine Beoku-Betts and Fredline A. M’Cormack-Hale eds. War, Women, and Post-Conflict Empowerment: Lessons from Sierra Leone , reviewed by Jillian LaBranche
by: Jillian LaBranche
Published: (2023-04-01)

Sexually transmitted founder HIV-1 viruses are relatively resistant to Langerhans cell-mediated restriction.
by: Nina Hertoghs, et al.
Published: (2019-01-01)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
by: Sunil K. Khattar, et al.
Published: (2015-09-01)

Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes
by: Jesus F. Salazar-Gonzalez, et al.
Published: (2016-07-01)

Cardiomiopatía periparto Peripartum cardiomyopathy
by: Jorge E Velásquez V, et al.
Published: (2008-02-01)

HIV-1 subtype C transmitted founders modulate dendritic cell inflammatory responses
by: Evelyn Ngwa Lumngwena, et al.
Published: (2020-07-01)

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer
by: Neeti Ananthaswamy, et al.
Published: (2019-02-01)

Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1
by: Bernadien M. Nijmeijer, et al.
Published: (2019-07-01)

Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
by: Sunil K Khattar, et al.
Published: (2013-01-01)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector.
by: Sunil K. Khattar, et al.
Published: (2014-01-01)

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.
by: Sean P O'Brien, et al.
Published: (2019-04-01)

Ontogeny of CD8+T Cells in Acute HIV-1 that Inhibit Autologous and Heterologous Transmitted/Founder (T/F) Viruses
by: Freel, SA, et al.
Published: (2011)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
by: Han D, et al.
Published: (2012-09-01)

The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity
by: Jennifer A. Jenks, et al.
Published: (2019-09-01)

Sexually transmitted founder HIV-1 viruses are relatively resistant to Langerhans cell-mediated restriction
by: Borrow, P, et al.
Published: (2019)

A deeper view of transmitted/founder viruses using 454 whole genome deep sequencing
by: Tully DC, et al.
Published: (2012-09-01)

Peripartum Cerebral Angiopathy
by: Amr Sallam, et al.
Published: (2023-03-01)

PP 7.13 – 00090 Early evolution of HIV-1 from transmitted founders during acute infection
by: V. Boltz, et al.
Published: (2022-12-01)

Transmitted/Founder Hepatitis C Viruses Induce Cell-Type- and Genotype-Specific Differences in Innate Signaling within the Liver
by: Angela M. Mitchell, et al.
Published: (2015-05-01)

Peripartum Cardiomyopathy
by: Riccardo Raddino, et al.
Published: (2016-01-01)

Peripartum Cardiomyopathy
by: T. G.A. Leonard
Published: (2019-04-01)

Protection against SHIV Challenge by Subcutaneous Administration of the Plant-Derived PGT121 Broadly Neutralizing Antibody in Macaques.
by: Yvonne J Rosenberg, et al.
Published: (2016-01-01)

Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV‑1 V3 Glycopeptide Vaccine
by: Hui Cai, et al.
Published: (2018-05-01)

Primary Presentation of Pulmonary Hypertension in the Peripartum
by: Malamo E. Countouris, MD, et al.
Published: (2020-01-01)

Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted/founder sensitivity to broadly neutralizing antibodies
by: Durgadevi Parthasarathy, et al.
Published: (2024-08-01)

Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells.
by: Daniel O Ochiel, et al.
Published: (2010-12-01)